Celgene Corporation Has "Optionality and Opportunity"

Celgene (NASDAQ: CELG) got crushed after announcing third-quarter earnings, saying revenue would come in at the bottom of previous guidance, and lowering its 2020 guidance. All things considered, though, the biotech isn't in that bad of a shape: It still expects to grow revenue and earnings by double digits over the next three years.

Metric

Q3 2017

Source: Fool.com